These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9952243)

  • 1. Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones.
    van de Heijning BJ; van de Meeberg PC; Portincasa P; Doornewaard H; Hoebers FJ; van Erpecum KJ; Vanberge-Henegouwen GP
    Dig Dis Sci; 1999 Jan; 44(1):190-6. PubMed ID: 9952243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones.
    Mas MR; Comert B; Mas N; Yamanel L; Ozotuk H; Tasci I; Jazrawi RP
    World J Gastroenterol; 2007 Aug; 13(32):4336-9. PubMed ID: 17708607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ursodeoxycholic acid on gallbladder contraction and cholecystokinin release in gallstone patients and normal subjects.
    van Erpecum KJ; van Berge Henegouwen GP; Stolk MF; Hopman WP; Jansen JB; Lamers CB
    Gastroenterology; 1990 Sep; 99(3):836-42. PubMed ID: 2199291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones.
    Fischer S; Müller I; Zündt BZ; Jüngst C; Meyer G; Jüngst D
    Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):305-11. PubMed ID: 15195895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones.
    Guarino MP; Cong P; Cicala M; Alloni R; Carotti S; Behar J
    Gut; 2007 Jun; 56(6):815-20. PubMed ID: 17185355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients.
    Carotti S; Guarino MP; Cicala M; Perrone G; Alloni R; Segreto F; Rabitti C; Morini S
    Neurogastroenterol Motil; 2010 Aug; 22(8):866-73, e232. PubMed ID: 20426797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophilic but not hydrophobic bile acids prevent gallbladder muscle dysfunction in acute cholecystitis.
    Xiao ZL; Biancani P; Carey MC; Behar J
    Hepatology; 2003 Jun; 37(6):1442-50. PubMed ID: 12774024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile lithogenicity and gallbladder emptying in patients with microlithiasis: effect of bile acid therapy.
    Sharma BC; Agarwal DK; Dhiman RK; Baijal SS; Choudhuri G; Saraswat VA
    Gastroenterology; 1998 Jul; 115(1):124-8. PubMed ID: 9649467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective gallbladder contractility in the ground squirrel and prairie dog during the early stages of cholesterol gallstone formation.
    Fridhandler TM; Davison JS; Shaffer EA
    Gastroenterology; 1983 Oct; 85(4):830-6. PubMed ID: 6309603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of gallbladder cholecystokinin: a receptor in prairie dogs fed a high-cholesterol diet and its dissociation with decreased contractility in response to cholecystokinin.
    Kano M; Shoda J; Satoh S; Kobayashi M; Matsuzaki Y; Abei M; Tanaka N
    J Lab Clin Med; 2002 May; 139(5):285-94. PubMed ID: 12032489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones.
    Miettinen TE; Tarpila S; Gylling H
    Hepatology; 1997 Mar; 25(3):514-8. PubMed ID: 9049189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid reduces protein levels and nucleation-promoting activity in human gallbladder bile.
    Van Erpecum KJ; Portincasa P; Eckhardt E; Go PM; VanBerge-Henegouwen GP; Groen AK
    Gastroenterology; 1996 Apr; 110(4):1225-37. PubMed ID: 8613013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice.
    Kim JK; Cho SM; Kang SH; Kim E; Yi H; Yun ES; Lee DG; Cho HJ; Paik YH; Choi YK; Haam SJ; Shin HC; Lee DK
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1745-51. PubMed ID: 22849613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallbladder motility in cholesterol gallstone disease. Effect of ursodeoxycholic acid administration and gallstone dissolution.
    Festi D; Frabboni R; Bazzoli F; Sangermano A; Ronchi M; Rossi L; Parini P; Orsini M; Primerano AM; Mazzella G
    Gastroenterology; 1990 Dec; 99(6):1779-85. PubMed ID: 2227291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis.
    Tomida S; Abei M; Yamaguchi T; Matsuzaki Y; Shoda J; Tanaka N; Osuga T
    Hepatology; 1999 Jul; 30(1):6-13. PubMed ID: 10385632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid protects interstitial Cajal-like cells in the gallbladder from undergoing apoptosis by inhibiting TNF-α expression.
    Wan JF; Chu SF; Zhou X; Li YT; He WB; Tan F; Luo P; Ai QD; Wang Q; Chen NH
    Acta Pharmacol Sin; 2018 Sep; 39(9):1493-1500. PubMed ID: 29770794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential site of disordered gallbladder contractility during the early stage of cholesterol gallstone formation.
    Mansour A; Dawoud I; Gad-El-Hak N
    Hepatogastroenterology; 1998; 45(23):1404-9. PubMed ID: 9840074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.
    Jüngst C; Sreejayan N; Zündt B; Müller I; Spelsberg FW; Hüttl TP; Kullak-Ublick GA; del Pozo R; Jüngst D; von Ritter C
    Eur J Clin Invest; 2008 Sep; 38(9):634-9. PubMed ID: 18837739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.
    Hillebrant CG; Nyberg B; Gustafsson U; Sahlin S; Björkhem I; Rudling M; Einarsson C
    Eur J Clin Invest; 2002 Jul; 32(7):528-34. PubMed ID: 12153554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid.
    Méndez-Sánchez N; Panduro A; Murguía D; Rincón AR; Uribe M
    Ann Hepatol; 2002; 1(2):85-9. PubMed ID: 15115973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.